Friedreich's Ataxia- Treatment Algorithm and Competitive Landscape 2017
NEW YORK, Dec. 5, 2017 /PRNewswire/ -- Friedreich's ataxia is a rare inherited autosomal recessive disorder that causes nervous system damage and movement problems.
Read the full report: https://www.reportlinker.com/p05232349
It is caused by a mutation in a gene labeled frataxin (FXN). Over time this deficiency causes the aforementioned damage, as well as frequent fatigue due to effects on cellular metabolism. Friedreich's ataxia is the most common of the autosomal recessive ataxias. Patients are prone to heart diseases like hypertrophic cardiomyopathy, which enlarges and weakens the heart muscle and can be life-threatening. Some affected individuals develop diabetes or an abnormal curvature of the spine.
According to the latest report of DelveInsight, "Friedreich's Ataxia– Treatment Algorithm and Competitive Landscape, 2017", Friedreich ataxia (FRDA) is the most common inherited ataxia in Europe, the Middle East, South Asia (Indian subcontinent), and North Africa. It is estimated to affect 1 in 40,000 people in the United States.
Currently, there are more than 20 active pipeline products undergoing development in different clinical stages. Even at this stage there is no cure for this problem, available treatments are only focused on reducing the symptoms of disease effectively.
Some drugs that are currently in the pipeline Phase II includes RT001 (Retrotope), Epicatechin (Cardero Therapeutics), ABT-RTA 408 (Reata Pharmaceuticals), JOT101 (Jupiter Orphan Therapeutics), TAK-831 (Takeda), and Vatiquinone (Edison Pharmaceuticals). 3 drugs are in phase 1, 11 in preclinical and 3 in discovery phase. Currently, there are no drugs in the clinical phase III for the treatment of Friedreich's Ataxia. There are several guidelines for the management and treatment of the disease provided by various US, Europe, and Australian clinicians. Europe– European Federation of neurological societies Guidelines, Australia- National Health and Medical Research Council (NHMRC) Australia, US- Friedreich's Ataxia Research Alliance (FARA), Consensus Clinical Management Guidelines for Friedreich's Ataxia.
The latest report has covered a detailed description of Diagnosis, Management and Treatment in Europe, US and Other Countries. Information about all the collaborations, financing and licensing deals. Complete Pipeline drugs profiling covering each and every phase of development. Not only pipeline drugs but the detailed description of the pre-clinical, discovery and inactive products is also provided in the report. Treatment algorithm and competitive is the main focus of this report making it a complete package for understanding the complete market scenario. Details about all the possible market drivers and barriers are also provided to better understand the areas of improvement and to plan the strategies accordingly.
Reasons to buy:
The report will help in developing business strategies by understanding trends shaping and driving the FRDA market.
To understand the future market competition in the FRDA market and Insight reviews of the key market drivers and barriers.
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
In-depth understanding of the pipeline development and recent happenings will provide a competitive edge over competitors.
Read the full report: https://www.reportlinker.com/p05232349
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article